Preventive effects of Hangeshashinto for severe pharyngeal mucositis during radiotherapy for hypopharyngeal and laryngeal cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs071200010

Enrollment

Registered

2020-04-24

Start date

2020-08-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypopharyngeal cancer, laryngeal cancer Hypopharyngeal cancer, laryngeal cancer, pharyngeal mucositis

Interventions

When grade 1 pharyngeal mucositis develop, patients of intervention group receive administration of Hangeshashinto.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with hypopharyngeal and laryngeal cancer undergoing radiotherapy

Exclusion criteria

Exclusion criteria: Patients with problem in judgement

Design outcomes

Primary

Measure	Time frame
Incident and radiation dose on the onset of grade 2 pharyngeal mucositis	—

Secondary

Measure	Time frame
Investigation of factors related to development of grade 2 pharyngeal mucositis	—

Contacts

Public ContactYumiko Kawashita

Nagasaki University Hospital

yumiko-t@nagasaki-u.ac.jp+81-95-819-7663

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026